NCT05383378View on ClinicalTrials.gov

A First-In-Human Study to Evaluate the Safety, Tolerability, and Efficacy of Si-544 in Adults With Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 30, 2022

Primary Completion Date

November 1, 2023

Study Completion Date

November 1, 2023

Conditions
Atopic Dermatitis
Interventions
DRUG

si-544

Subcutaneous injection in the abdomen

DRUG

Placebo

Subcutaneous injection in the abdomen

Trial Locations (5)

Unknown

selectION Clinical Trial Site, Berlin

selectION Clinical Trial Site, Hamburg

selectION Clinical Trial Site, Magdeburg

selectION Clinical Trial Site, Mainz

selectION Clinical Trial Site, Wuppertal

Sponsors
All Listed Sponsors
collaborator

FGK Clinical Research GmbH

INDUSTRY

lead

selectION Therapeutics GmbH

INDUSTRY